anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention discloses a liquid wound plaster. Raw material of the liquid wound plaster comprises 0.5 to 15 parts of polyvinyl acetal, 1 to 3 parts of silicone oil, 0.5 to 20 parts of chitin, 0.5 to 20 parts of alcohol, 0.5 to 5 parts of acetone, 1 to 5 parts of nano silver, 0.5 to 3 parts of glycerol, 1 to 5 parts of dibutyl ester, 0.5 to 1 part of peppermint oil, 1 to 6 parts of medical stone powder and 3 to 10 parts of distilled water. The liquid wound plaster has the functions of sterilization, bacteriostasis, detumescence, hemostasis and pain alleviation; however, by using the liquid wound plaster, the liquid wound plaster does not have a side effect and can not generate medicine resistance performance. Simultaneously, the liquid wound plaster is isolated from water and can not stick with clothes and bedding. The part where the liquid wound plaster is coated can move freely. The wound plaster has convenient application and disassembly. Compared with the existing similar product, the present invention has the advantage of no limit by the size and the shape of a wound, and is suitable for any position on bodies. The present invention simultaneously provides a preparing method of the liquid wound plaster.
PROBLEM TO BE SOLVED: To provide a pharmaceutical with which improved effects are obtained in comparison with medicaments used in conventional photodynamic therapy. SOLUTION: A pyropheophorbide compound and a pharmaceutical composition containing the same are obtained and a therapeutic method using the compound in photodynamic therapy is provided. When the pyropheophorbide compound is injected to a host, it is accumulated in tumor tissues in higher concentration than in surrounding normal tissues. When the pyropheophorbide compound is irradiated with a light having a specific wave length, the compound becomes to be cytotoxic and destroys the tumor tissues or morbid tissues without generating irreversible damages to the normal tissues. The pyropheophorbide compound has expressed an improved result in comparison with conventional pharmaceuticals used in the photodynamic therapy.  The compound absorbs deeper red lights, has optimum tissue permeability in comparison with other pharmaceuticals used in the photodynamic therapy and is retained in the skin for a short term.
The treatment group will participate in supervised Resonating Arm Exerciser (RAE) group sessions of 45 minutes, three times a week, for a total of eight sessions for three consecutive weeks. During each treatment session, the affected upper extremity will be used to push on the lever of the RAE in the sagittal plane. Upon pushing and pulling on the lever, the wheelchair moves a total of 20 cm from a neutral position, which indicated a repetition counted by a programed iphone.
BACKGROUND AND AIMS: Colonoscopies are routinely obtained before liver transplantation, although their utility is a highly debated topic in the literature. We aimed to determine the risk factors in patients with decompensated cirrhosis (DC) for post-colonoscopy complications (PCC).
MATERIALS AND METHODS: We performed a single-center retrospective study of patients with DC undergoing colonoscopy as part of their pre-liver-transplant evaluation. The primary composite outcome was defined as a complication occurring within 30 days of the colonoscopy. Complications included acute renal failure, new or worsening ascites or hepatic encephalopathy, gastrointestinal bleeding, or any cardiopulmonary or infectious complication. Logistic regression analysis was utilized to derive a risk score in predicting the primary composite outcome.
RESULTS: The strongest predictors of post-colonoscopy complication were MELD-Na ≥21 [aOR 4.0026 ( P =0.0050)] and history of any infection in the 30 days before colonoscopy [aOR 8.4345 ( P =0.0093)]. The area under the receiver operating characteristic curve of the final model was 0.78. The predicted risk of any complication at the lowest quartile was 16.2% to 39.4%, and the observed risk was 30.6% (95% CI: 15.5-45.6%), while the predicted risk at the highest quartile was 71.9% to 97.1%, and the observed risk was 81.3% (95% CI: 67.7-95%).
CONCLUSION: In this cohort of patients with DC undergoing colonoscopy for pre-liver-transplant evaluation, a history of ascites, spontaneous bacterial peritonitis, and MELD-Na were found to be predictive of PCC. This risk score may help to predict PCC in patients with DC undergoing a pre-transplant colonoscopy. External validation is recommended.
The English version of the Oxford Shoulder Score Scale will be translated and culturally modified into Urdu. The Oxford Shoulder Score Scale, as well as other correlation measures, will be disseminated among 104 individuals in the Pakistani Urdu speaking community, who will be chosen using a convenience sample approach and based on pre-defined inclusion and exclusion criteria. For the intra- and inter-observer validity and reliability of the Oxford Shoulder Score Scale, Shoulder Pain And Disability Index, and Short Form - 36, questionnaires will be filled on the same day by two observers, with a two-hour gap between the first and second application. This is the inter-observer evaluation. The third application for the intra-observer evaluation will be completed after 7 days. Statistical Package of Social Sciences Version 26 will be used to enter and analyses the data. The internal consistency will be assessed using the Cronbach alpha value. The test-retest reliability will be assessed using an inter-class correlation coefficient. The content validity, criteria and construct validity, as well as responsiveness, of the Oxford Shoulder Score Scale scale will be assessed.
An ECG monitoring system for ambulatory patients includes a small multi-electrode patch that adhesively attaches to the chest of a patient. A reusable battery-powered ECG monitor clips onto the patch and receives patient electrical signals from the electrodes of the patch. ECG data is sent to a cellphone handset which relays the data to a monitoring center. After the monitoring procedure is completed, the monitoring system kit of components is returned to a refurbishment center. The kit components are there serviced for use in another kit for a subsequent monitoring procedure. The servicing includes deleting patient data from the components, cleaning them, verifying their operability, and performing self-testing. At the conclusion of servicing the components are put back into inventory for use in a monitoring kit in the future.
Chronic infection with the hepatitis B virus (HBV) induces progressive hepatic impairment. Achieving complete eradication of the virus remains a formidable challenge. Cytotoxic T lymphocytes, specific to viral antigens, either exhibit a numerical deficiency or succumb to an exhausted state in individuals chronically afflicted with HBV. The comprehension of the genesis and dissemination of stem cell memory T cells (TSCMs) targeting HBV remains inadequately elucidated. We identified TSCMs in subjects with chronic HBV infection and scrutinized their efficacy in a murine model with human hepatocyte transplants, specifically the TK-NOG mice. TSCMs were discerned in all subjects under examination. Introduction of TSCMs into the HBV mouse model precipitated a severe necro-inflammatory response, resulting in the elimination of human hepatocytes. TSCMs may constitute a valuable tool in the pursuit of a remedial therapy for HBV infection.
PURPOSE:To obtain the title polyfunctional oligomer having ultraviolet curability and being useful as a printing ink binder, by reacting two specified reaction products with a diisocyanate. CONSTITUTION:100pts.wt. mixture containing (meth)acrylic acid (i) and rosin glycidyl ester (ii) at a molar ratio of 1:0.9-1.1 is reacted at 80-130 deg.C for 3-10hr in the presence of 0.1-2pts.wt. esterification catalyst (iii) and 0.001-0.5pt.wt. polymerization inhibitor (iv) to obtain a reaction product (A) of formula I (wherein R1 is a rosin residue and R2 is H or CH3). Separately, a mixture of component (i) with an epoxidized vegetable oil (v) at a molar ratio of 2-4:1 is reacted in the presence of components (iii) and (iv) to obtain a reaction product (C) of formula II (wherein X is any one of formulas III-IV, and a+b, c+d and e+f are each 6-20). Component A is reacted with a diisocyanate (B) at a molar ratio of 1:0.8-1.2 and reacted at 50-100 deg.C for 1-5hr to obtain an intermediate, and this intermediate is mixed with component C at a molar ratio of 2.5-0.5:1 and reacted at 50-100 deg.C for 1-5hr.
Safety and effectiveness of calcitriol in pediatric patients undergoing dialysis have not been established. The safety and effectiveness of calcitriol in pediatric predialysis patients is based on evidence from adequate and well-controlled studies of calcitriol in adults with predialysis chronic renal failure and additional supportive data from non-placebo controlled studies in pediatric patients. Dosing guidelines have not been established for pediatric patients under 1 year of age with hypoparathyroidism or for pediatric patients less than 6 years of age with pseudohypoparathyroidism (see DOSAGE AND ADMINISTRATION, Hypoparathyroidism).

Oral doses of calcitriol ranging from 10 to 55 ng/kg/day have been shown to improve calcium homeostasis and bone disease in pediatric patients with chronic renal failure for whom hemodialysis is not yet required (predialysis). Long-term calcitriol therapy is well tolerated by pediatric patients. The most common safety issues are mild, transient episodes of hypercalcemia, hyperphosphatemia, and increases in the serum calcium times phosphate (Ca x P) product which are managed effectively by dosage adjustment or temporary discontinuation of the vitamin D derivative.
A method and system for managing a workflow for producing a biostatistical analysis (BA) of biomedical data. The data originates from a milestone (or snapshot) of a clinical study performed by, or on behalf of a life science company that performs the BA. The data may be from a blinded or un-blinded clinical study. SAS programs are used for the BA. An audit trail is produced to track changes to any of the data or programs used during the course of the workflow. The programs and data used to produce reported results from the BA are stored in electronic format for sending to a regulatory agency.
INTRODUCTION: The aim of this study is to evaluate and compare erection function (EF) after Excision and Primary Anastomosis Urethroplasty (EPAU) and Buccal Mucosal Graft Urethroplasty (BMGU) in bulbar urethral stricture.
METHODS: Patients who underwent urethroplasty were identified retrospectively. The criteria for inclusion in the study were determined as being over 18 years old and under 70 years old, being sexually active. Exclusion criteria are; preoperative severe erectile dysfunction, stricture outside the bulbar urethra, psychosocial incompatibility, urethral stricture related to pelvic fracture, follow-up time less than a year. As the primary endpoint, the International Index of Erectile Function-5 (IIEF-5) was determined as a comparison of EF in the preoperative and third, sixth and twelfth months after surgery. The secondary endpoint was the evaluation of the effects of demographic data, stricture and treatment characteristics on EF.
RESULTS: Fifty patients were identified considering the inclusion/exclusion criteria. It was observed that there were 30 patients who underwent EPAU and 20 patients who underwent BMGU. At the third month after surgery, EF showed a statistically significant decrease in the EPAU group. In both patient groups, it was observed that the early negative effects after the operation in EF started to improve in the sixth month and returned to the baseline level by the first year.
CONCLUSION: EPAU and BMGU techniques have a similar effect on EF in the medium and long term. Both methods can be used safely and effectively in the appropriate patient group.
Intervention group 2: Patients in this group undergo ventilation with a nasal mask and 100% oxygen for three minutes. Ventilation will be performed with the controlled mode of the anesthesia machine with a volume of 8 cc/kg and a speed of 12-20/min.
A cannabidiol (CBD) preparation for use in the treatment of seizures associated Malignant Migrating Partial Epilepsy of Infancy (MMPSI). The seizures may be focal seizures with secondary generalisation and focal seizures with impairment. The preparation may comprise greater than 95% CBD and not more than 0.15% THC. The preparation may be used in combination with one or more concomitant anti-epileptic drugs (AEDs), such as levetiracetam, clobazam, rufinamide, topiramate, stiripentol and phenobarbital. The CBD may be isolated from cannabis plant material or as a synthetic preparation. The dose of CBD may be between 5mg/kg/day and 50mg/kg/day. Also claimed is a method of treating seizures associated with MMPSI comprising administering a cannabidiol preparation to the subject in need thereof.
Gallbladder and Biliary Tract Disease

Cholecystitis, cholangitis, and cholelithiasis have been reported in clinical studies [see Adverse Reactions (6.1)] and postmarketing. For identification of the onset or worsening of gallbladder/biliary disease, obtain laboratory assessment of bilirubin and alkaline phosphatase within 6 months prior to starting GATTEX, and at least every 6 months while on GATTEX; or more frequently if needed. If clinically meaningful changes are seen, further evaluation including imaging of the gallbladder and/or biliary tract is recommended; and reassess the need for continued GATTEX treatment.

Pancreatic Disease

Pancreatitis has been reported in clinical studies [see Adverse Reactions (6.1)]. For identification of onset or worsening of pancreatic disease, obtain laboratory assessments of lipase and amylase within 6 months prior to starting GATTEX, and at least every 6 months while on GATTEX; or more frequently if needed. If clinically meaningful changes are seen, further evaluation such as imaging of the pancreas is recommended; and reassess the need for continued GATTEX treatment.
This is the study entitled "The outcome of CPAP titration under sleep endoscopy: A randomized controlled crossover trial". CPAP is first line golden standard treatment for Obstructive sleep apnea (OSA). However, the overall CPAP compliance is about 50%. One of the reasons responsible for the poor compliance is the inadequate pressure setting initially. Therefore, it is crucial for us to find out the adequate pressure as soon as possible. Sleep endoscopy is the way to evaluate upper airway obstruction of OSA patients. Meanwhile, the investigators used CPAP to titrate the adequate pressure to keep upper airway open under sleep endoscopy guidance. While the investigators find out this adequate pressure, the investigators set this pressure into CPAP program, which OSA patient will use for 1 month. To compare the different effect of CPAP under either auto-CPAP titration pressure or sleep endoscopy guidance pressure, those OSA patients will use auto-titration CPAP for 1 month as well. Another highlight of this study is the sedative agent-dexmedetomidine. Dexmedetomidine is a α2 antogonist, which cause patients sedative but less respiratory drive suppression. The mechanism of dexmedetomidine is more physiological for nature sleep.
The potency units of MYOBLOC are specific to the preparation and assay method utilized. They are not interchangeable with other preparations of botulinum toxin products and cannot be compared to or converted into units of any other botulinum toxin products [see Warnings and Precautions (5.2), Description (11)] . 

Each single-dose vial should only be used during one session and only for one patient. Discard any remaining solution in the vial.

MYOBLOC is ready to use; no reconstitution required.

MYOBLOC may be diluted with 0.9% Sodium Chloride Injection. Once diluted, the product must be used within 4 hours as the formulation does not contain a preservative.
The study will include patients aged 18 years and over, with (American Society of Anesthesiologists) ASA physical status I to II, and scheduled for one or two-level lumbar disc herniation surgery under general anesthesia. Patient characteristics (age, gender, body mass index, etc.) and postoperative nausea and vomiting (PONV) risk factors such as history of PONV, motion sickness, and history of not smoking will be recorded. The primary outcome parameter will be the incidence of PONV within 24 hours postoperatively. The severity of nausea in patients who develop nausea in the postoperative period will be assessed using a Likert scale between 0 and 10. PONV will be defined as vomiting, significant nausea (numerical rating scale \[NRS\] ≥4), and/or need for rescue medication. Patients will be assessed for PONV at 0, 2, 4, 12, and 24 hours using a Likert scale. Emetic attacks, pain and severity of pain, nausea and severity of nausea, need for additional analgesics, and administration of antiemetic rescue medication will be assessed as secondary outcome parameters. The severity of pain and nausea in patients who develop postoperative pain will be assessed using an 11-point numerical rating scale, where '0' indicates the absence of symptoms and '10' indicates the maximum severity. PONV within the first two hours will be defined as 'early', and within 2-24 hours after awakening will be defined as 'late'. Nausea will be defined as the desire to vomit, and vomiting will be defined as the forceful expulsion of stomach contents.
At the beginning of the study, each subject of the case group will complete echo examination and related lab test for BNP. During the study, each subject will have a six minutes' walk test and 24 hour ambulatory monitoring while having an ActiGraph device placed on his/her wrist and a Holter device with ECG electrodes placed on his/her chest. The treadmill test is optional to patients per physicians' instruction and/or patients' own judgment. It would be performed at the end of the study if chosen.
OBJECTIVE: Childhood hearing impairment has potential repercussions on the mental well-being of both children and their parents. As a vulnerable population in accessing health care services, they may face specific challenges, especially during the COVID-19 pandemic. This cross-sectional study aims to investigate the association between childhood hearing impairment and the mental health of children and their parents, and to assess health care utilization of hearing-impaired children and its impact on mental outcomes for both during the COVID-19 pandemic.
METHODS: Using the National Health Interview Survey (NHIS) database, we analyzed data for 15,989 children aged 5-17 and their corresponding parents. The correlations between childhood hearing impairment and mental outcomes were examined using logistic regression models. The 2020 (quarter 3 and quarter 4)-2021 NHIS data was singled out and re-analyzed, focusing on the utilization of medical care during the COVID-19 pandemic.
RESULTS: After accounting for covariates, hearing-impaired children exhibited a higher frequency of anxiety (OR 2.33, 95% CI 1.79-3.02) or depression (OR 2.14, 95% CI 1.59-2.88). Parents of hearing-impaired children had significantly higher odds of a higher frequency of anxiety (OR 1.55, 95% CI 1.20-2.01) or depression (OR 1.73, 95% CI 1.30-2.29). Interaction effect of hearing impairment with survey year on parents' mental health outcomes was observed (p for interaction <0.1). Children with hearing loss had higher odds of reporting delayed medical care (OR 2.00, 95% CI 1.11-3.59) or canceled medical care (OR 1.96, 95% CI 0.98-3.96, p = 0.059) due to the pandemic. Delayed medical care (OR 12.41, 95% CI 2.78-55.46) or canceled medical care (OR 6.26, 95% CI 1.28-30.75) due to the COVID-19 pandemic significantly contributed to the increase of anxiety frequency in hearing-impaired children.
CONCLUSION: Childhood hearing impairment exhibits a substantial impact on children's and parental mental health, which is further exacerbated by the COVID-19 pandemic. Families of hearing-impaired children appear to be in a vulnerable position during public health emergencies such as the COVID-19 pandemic, which can further exacerbate their mental outcomes.
Lifileucel (LN-144) is an autologous Tumor Infiltrating Lymphocytes (TIL) cell therapy. A tumor sample is resected from each patient for lifileucel manufacturing. Patients then receive the lifileucel regimen which consists of a reduced dose non-myeloablative lymphodepletion, lifileucel infusion followed by interleukin-2.
PURPOSE: A composition containing a Capsella sp. extract as an active ingredient is provided to show antibacterial activity against Bacillus anthracis and antibiotics resistant bacteria, thereby being used as a pharmaceutical composition for preventing or treating infectious diseases and anthrax. CONSTITUTION: An antibacterial or anti-inflammatory composition against Bacillus anthracis and antibiotics resistant bacteria contains a Capsella sp. extract as an active ingredient. The extract is prepared using water or an organic solvent. The organic solvent is selected among methanol, ethanol, propanol, isopropanol, butanol, acetone, ether, benzene, chloroform, ethyl acetate, and methylene chloride. A pharmaceutical composition for preventing or treating infectious diseases contains the composition.
NEW MATERIAL:The compound of formula I [one of A1 and A2 is H and the other is notroso; R is group of formula II (R1 and R2 are H or lower alkyl); n is 0 or 1]. EXAMPLE:2-[3-(2-Chloroethyl)-1-nitrosoureido]methyl-cyclo-2-pe-nt-enone. USE:Antitumor agent. PREPARATION:The compound of formula I can be prepared by nitrosating 1 equivalent of the urea compound of formula III with 1-1.5 equivalent of nitrous acid prepared by the reaction of an nitrous acid salt with an inorganic acid or organic acid, in formic acid, acetic acid, etc. or their mixture with water, at room tempeature for 1-5hr. The starting urea compound of formula III is obtained by reacting a halide with silver cyanate, and reacting the resul tant organic isocyanate with 2-chloroethylamine hydrochloride in the presence of pyridine, triethylamine, etc.
A photosensitiser for use in a method of treatment of a pathogenic infection, wherein said treatment comprises (i) contacting a pathogen residing in the oral cavity and/or pharynx with the photosensitizer and (ii) subjecting the photosensitizer contacted pathogen to a light source is provided. The pathogenic infection is preferably a viral infection selected from SARS-CoV-2, SARS, MERS, swine flu or Zika. The photosensitiser may be methylene blue, riboflavin or a combination thereof. The light source may be a laser diode, light-emitting diode, infrared and enhanced pulsed light beam or a combination thereof. The contacting may comprise flushing or gargling the photosensitiser or by application of a viscous formulation. The photosensitiser may be administered by oral ingestion. A photosensitiser for using in treating SAR-CoV-2 infection or other infection by systemically administrating the photosensitiser followed by sublingual administration of light to excite the photosensitiser is provided. A photosensitiser for using in treating a SAR-CoV-2 mediated disease in a a subject by systemically administrating the photosensitiser followed by sublingual administration of light to excite the photosensitiser is provided. The SAR-CoV-2 mediated disease is COVID-19. The photosensitiser is preferably methylene blue.